AXGN
HealthcareAxoGen, Inc. · Medical - Devices · $2B
What is AxoGen, Inc.?
AxoGen is a medical technology company focused exclusively on peripheral nerve repair — a niche but clinically significant area of regenerative surgery. Headquartered in Alachua, Florida, the company serves surgeons across hospitals, surgery centers, and military medical facilities.
AxoGen develops and markets a portfolio of surgical products designed to repair, protect, and reconstruct damaged peripheral nerves. Its revenue comes from selling biologically derived and processed tissue products to plastic reconstructive surgeons, orthopedic and hand surgeons, and oral and maxillofacial surgeons. The company operates primarily in the United States and Canada, supplying both civilian and military healthcare settings with off-the-shelf nerve repair solutions that eliminate the need for a second surgical harvest site.
AxoGen was founded in 1986 and is headquartered in Alachua, Florida.
- Avance Nerve Graft — processed human nerve allograft for bridging severed nerves
- AxoGuard Nerve Connector — porcine ECM coaptation aid for tensionless nerve repair
- AxoGuard Nerve Protector — ECM wrap to protect and reinforce damaged peripheral nerves
- AxoGuard Nerve Cap — ECM product to protect nerve ends and reduce painful neuroma
- Avive Soft Tissue Membrane — processed umbilical cord membrane for soft tissue coverage
Is AXGN a Good Stock to Buy?
UQS Score rates AXGN as Below Average overall, reflecting meaningful structural challenges alongside some areas of relative strength.
The Risk pillar stands out as the clearest positive — AxoGen carries a profile that suggests manageable downside exposure relative to many peers in the healthcare device space. The Growth pillar also earns a Good rating, indicating the company is expanding its commercial footprint in a specialized and underpenetrated market.
Both the Quality and Moat pillars register as Weak, pointing to limited durable competitive advantages and profitability characteristics that trail stronger peers in the sector.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AXGN pay dividends?
No — AxoGen, Inc. does not currently pay a dividend.
AxoGen does not currently pay a dividend. For a company at this stage of commercial development, retaining capital to fund product adoption, clinical evidence generation, and sales force expansion is the typical strategic priority. Income-focused investors should factor this into their overall portfolio planning.
When does AXGN report earnings?
AxoGen reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar rating suggests revenue momentum has been building, though Quality metrics indicate profitability remains a work in progress. Investors should track quarterly updates for signs of operating leverage emerging from the expanding commercial base.
For the most recent quarter's results and guidance, visit AxoGen's investor relations page directly.
AXGN Price History
+165.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in AxoGen, Inc.?
Based on AxoGen, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AXGN Long-term Outlook
AxoGen's fundamental outlook is shaped by two competing forces: a Good Growth profile that reflects genuine commercial traction in peripheral nerve repair, and Weak Quality and Moat ratings that signal the path to durable profitability remains uncertain. The Strong Risk rating provides some reassurance that near-term financial stability is not a primary concern. Valuation is currently rated Neutral, suggesting the market has priced in a moderate growth scenario without obvious excess.
Growth drivers
- Underpenetrated peripheral nerve repair market with growing surgeon adoption
- Expanding product portfolio addressing multiple stages of nerve reconstruction
- Military and specialty hospital channel providing diversified demand
Key risks
- Weak Moat rating signals limited pricing power and competitive differentiation risk
- Weak Quality pillar points to ongoing profitability and return-on-capital challenges
- Neutral Valuation leaves little margin of safety if growth expectations moderate
AXGN vs Peers
AxoGen operates in a niche segment of the broader medical device and biologics landscape, where it competes indirectly with companies addressing adjacent surgical and reconstructive needs.
Establishment Labs focuses on breast aesthetics and reconstruction implants, competing for surgical budget and OR time rather than directly overlapping with nerve repair.
Artivion specializes in cardiac and vascular tissue processing, sharing AxoGen's reliance on processed biological grafts but serving a different surgical specialty.
AdaptHealth operates in home medical equipment and respiratory therapy, representing a broader healthcare services model distinct from AxoGen's surgical biologics focus.
Frequently Asked Questions
What does AxoGen do?
AxoGen develops and sells surgical products for peripheral nerve repair. Its portfolio includes processed human nerve allografts and porcine-derived tissue products that surgeons use to bridge, protect, and reconstruct damaged nerves — without requiring a second surgical harvest site from the patient.
Does AXGN pay dividends?
No, AxoGen does not currently pay a dividend. The company is in a growth phase and retains capital to fund commercial expansion and product development rather than returning cash to shareholders through distributions.
When does AXGN report earnings?
AxoGen reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact dates and the most recent results, check AxoGen's investor relations page, as our data source does not cover specific upcoming earnings dates.
Is AXGN a good stock to buy?
UQS Score rates AXGN as Below Average overall. The Growth and Risk pillars show relative strength, but Weak Quality and Moat ratings highlight real challenges. Whether it fits your portfolio depends on your risk tolerance and investment thesis — view the full pillar breakdown on UQS Pro.
Is AXGN overvalued?
The UQS Valuation pillar for AXGN is rated Neutral, suggesting the current market price reflects a balanced — neither clearly cheap nor obviously expensive — view of the company's growth prospects relative to its fundamentals.
How does AXGN compare to its competitors?
AxoGen occupies a highly specialized niche in peripheral nerve repair biologics. Peers like Artivion operate in adjacent tissue-processing markets, while Establishment Labs and AdaptHealth address different surgical and healthcare service segments. UQS Pro shows side-by-side pillar comparisons for a deeper view.
What is AXGN's market cap bracket?
AxoGen is classified as a mid-cap company. This places it in a bracket that typically offers more growth optionality than large-caps but with greater volatility and liquidity considerations than mega-cap healthcare names.
Who founded AxoGen?
AxoGen traces its origins to 1986. Detailed founding history, including original founders, is publicly available through the company's official corporate history and SEC filings on its investor relations site.
Is AXGN a long-term quality indicator?
As a long-term quality indicator, AXGN's UQS profile is mixed. The Good Growth rating suggests commercial momentum, but Weak Quality and Moat scores indicate the company has not yet demonstrated the durable competitive advantages and consistent profitability that typically characterize high-quality long-term holdings.
What is the main competitive advantage of AxoGen?
AxoGen's primary competitive position comes from its specialized focus on peripheral nerve repair and its portfolio of off-the-shelf biological products. However, the UQS Moat pillar rates this advantage as Weak, suggesting the company faces meaningful competition and has limited pricing power relative to stronger-moat peers.
What sector does AXGN belong to?
AxoGen operates in the Healthcare sector, specifically within the medical devices and biologics subsegment. It focuses on a narrow but clinically important area — surgical solutions for peripheral nerve damage — serving plastic, orthopedic, hand, and oral surgeons.
Is AXGN a growth stock or value stock?
Based on its UQS profile, AXGN leans toward the growth category — the Growth pillar earns a Good rating while Valuation is Neutral. It is not a deep-value play, nor does it carry the premium valuation of a high-conviction growth stock. It sits in an in-between zone.
Unlock Full AXGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access full financial metrics and trend data
- ✓Compare AXGN side-by-side with sector peers
- ✓See the complete Quality and Moat breakdown
- ✓Track score changes as new earnings data arrives
- ✓Filter top-rated Healthcare stocks by pillar strength
Pro Analysis
AXGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | 11.0 | 0.3 | 25.0 | 0.0 | 30.8 | 0.0 | -28.8 |
| Jul 31, 2026 | 39.8 | 16.9 | 25.0 | 70.9 | 47.1 | 54.3 | -0.4 |
| Jul 25, 2026 | 40.2 | 17.6 | 25.0 | 70.9 | 47.1 | 55.7 | 0.0 |
| Jul 24, 2026 | 40.2 | 17.5 | 25.0 | 70.9 | 47.1 | 55.7 | 0.0 |
| Jul 23, 2026 | 40.2 | 17.6 | 25.0 | 70.9 | 47.1 | 55.8 | 0.0 |
| Jul 22, 2026 | 40.2 | 17.5 | 25.0 | 70.9 | 47.1 | 55.5 | 0.0 |
| Jul 21, 2026 | 40.2 | 17.6 | 25.0 | 70.9 | 47.1 | 55.7 | 0.0 |
| Jul 18, 2026 | 40.2 | 17.5 | 25.0 | 70.9 | 47.1 | 55.6 | 0.0 |
| Jul 17, 2026 | 40.2 | 17.5 | 25.0 | 70.9 | 47.1 | 55.7 | -0.1 |
| Jul 15, 2026 | 40.3 | 17.6 | 25.0 | 70.9 | 47.1 | 55.9 | +0.1 |
AXGN — Pillar Breakdown
Quality
— 0.3/100 (25%)AxoGen, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)AxoGen, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 30.8/100 (15%)AxoGen, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)AxoGen, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 25/100 (25%)AxoGen, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AXGN.
Score Composition
Financial Data
More Stock Analysis
How is the AXGN UQS Score Calculated?
The UQS (Unified Quality Score) for AxoGen, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses AxoGen, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether AxoGen, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.